BioFreedom stent approved in Europe
| January 28, 2013 | Cardiovascular Business | Interventional Cardiology

BioFreedom, a polymer-free drug-coated stent, has received CE Mark approval in Europe.

BioFreedom (Biosensors International) features a microstructured abluminal surface that permits the controlled release of Biolimus A9 (BA9) without the use of a polymer. BA9 is a lipophilic antirestenotic drug developed by Biosensors specifically for use with stents, according to Singapore-based Biosensors.

BioFreedom showed a strong safety profile compared with the Taxus paclitaxel-eluting stent (Boston Scientific) in one-year results of the first-in-man BioFreedom trial. There were two versions of the stent used in the trial: the BioFreedom low dose and the BioFreedom standard dose. Both doses demonstrated sustained safety up to 12 months, including an absence of stent thrombosis, according to researchers. The one-year results were presented at the Transcatheter Cardiovascular Therapeutics conference in 2010.

Related Content

TAVR, SAVR linked to similar QOL improvements for intermediate-risk patients after five years
Q&A: Cleveland Clinic’s Lars Svensson previews AATS annual meeting
TAVR or SAVR? ChatGPT could help cardiologists decide
Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation
Q&A: Interventional cardiologist details key breakthroughs in tricuspid valve replacement and repair
Boston Scientific recalls premixed embolic agent after two deaths

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business
Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Design by Adaptive Theme
Trimed Popup
Trimed Popup